Cyclacel Pharmaceuticals
Berkeley Heights, New Jersey, United States · Biopharma, Biotechnology, Pharmaceutical · 13 employees
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis biology. The Company's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.
Funding history
- Series seed — $1.0M — Mar 2025
- Series series e — $1.0M — Mar 2025
- Series seed — $2.1M — Nov 2024
- Funding Round — $8.0M — May 2024
- Funding Round — $7.0M — Jan 2021
Recent signals
- Nov 06, 2025: Bio Green Med Solution Enters Warrant Exchange Agreement
- Nov 05, 2025: SEC 8-K (1.01): On November 5, 2025, Bio Green Med Solution, Inc. entered into a Warrant Exchange Agreement with certain accredited investors to exchange existing warrants for an aggregate of 1,402,605 shares of its common stock. This agreement signifies a strategic move by the Company to manage its equity and potentially strengthen its capital structure. The Exchanged Warrants were previously issued under a separate arrangement, and this new agreement aims to optimize investor relationships and financial flexibility. The event date aligns with the recent filing, confirming its relevance and timeliness.
- Mar 25, 2025: Raised $1.0M in Series seed
- Mar 24, 2025: Raised $1.0M in Series series e
- Dec 05, 2024: Launched Cyclacel Pharmaceuticals Announces Exploration of Strategic Alternatives to Preserve Cash and Reduce Costs.
- Nov 26, 2024: Raised $2.1M in Series seed
- Nov 14, 2024: Cyclacel Pharmaceuticals Closes Warrant Exercise, Raises $2.1 Million
- May 17, 2024: Raised $8.0M
See plans & pricing → Track Cyclacel Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.